...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
AGORACOM NEWS FLASH

Dear Agoracom Family,

I want to thank all of you for your patience with us over the past 48 hours and apologize for what was admittedly a botched launch of our new site.

As you can see, we have reverted back to the previous version of the site while we address multiple forum functionality flaws that inexplicably made their way into the launch.

To this end:

1.We have identified 8 fundamental but easily fixable flaws that will be corrected in the coming week, so that you can continue to use the forums exactly as you've been accustomed to.

2.Additionally we will also be implementing a couple of design improvements to "tighten up" the look and feel of the forums.

Have a great Sunday, especially those of you like me that are celebrating Orthodox Easter ... As well as those of you who are also like me and mourning another Maple Leafs Game 7 exit ... Ugggh!

Sincerely,

George et al

Message: QBI COVID-19 research results

In a  mad dash read through the PDF there are two references to "iBETs might disrupt the interaction between protein E and BRDs :

Early on, page 3 has a section specifically stating the SARS-CoV2 envelope interacts with BRD2 and BRD4 which is what got us in this paper. They do not elaborate on what that means, but hopefully RVX is working away behind the scenes to find out.   So, if Abet is not an active antiviral, (not surprising) potentially having the ability to effect the envelope is still hopeful that our horse isn't out of the race just yet.

Also, see Page 10 Fig. D(iii) that shows RVX-208 along with two others as clinical candidates of iBETs that may effect BRD2 and BRD4 interaction with E. 

Share
New Message
Please login to post a reply